October 2026
NanoPhoria publishes research
NanoPhoria publishes research in the Journal of Drug Delivery Science and Technology demonstrating the potency of dry powder inhalation technology.
About NanoPhoria
NanoPhoria is a preclinical-stage biotech company pioneering the next generation of cardiovascular treatments through an innovative inhaled, nano-in-micro delivery platform. Our mission is to transform the way therapeutic peptides and RNAs are delivered, enabling precise, tissue-directed treatment for complex cardiovascular conditions.
At the heart of our delivery technology is a proprietary nano-in-micro platform built on inorganic calcium phosphate nanoparticles embedded in highly respirable microparticles. CaP nanoparticles represent a versatile, biomimetic nanocarrier that can be loaded or surface-decorated with biologics. This non-viral, scalable system is designed for inhalation and other administration routes, offering a safe and effective alternative for advanced drug delivery.
Our lead product, NP-MP1, is an inhalable nano-in-micro formulation delivering a first-in-class calcium channel modulator peptide for the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF), which is a chronic syndrome impacting millions worldwide.
By combining cutting-edge nanotechnology with therapeutic innovation, NanoPhoria is redefining what’s possible in cardiovascular care.
TIMELINE
2026
November 2026
Alessio Alogna presents inhalation-based approach
Alessio Alogna, one of our founders, presents our inhalation-based approach to treat HFrEF in a large animal model at the American Heart Association’s annual Scientific Sessions event.
January 2026
Second closing of our series A round
NanoPhoria announces the second closing of our series A round to include participation from the European Innovation Council.
2025
October 2025
NanoPhoria secures €83.5m Italian Series A Biotech
NanoPhoria sets the record for the largest ever Italian Series A Biotech raise, securing €83.5m. The round was led XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with Panakès Partners participating.
2024
January 2024
New non-executive members to the Board of Directors
Dr Suman Shirodkar as chair and Prof. Michael Davidson as non-executive member of our Board of Directors
January 2024
NanoPhoria publishes first paper in JACC
NanoPhoria publishes first paper in JACC, demonstrating NP-MP1’s ability to improve ejection fraction by 17% ±6% in pig models, while also improving other cardiovascular markers.
February 2024
NanoPhoria awarded €17.5m
NanoPhoria awarded €17.5m by the European Innovation Council’s Accelerator Program
2022
February 2022
NanoPhoria receives seed grant
NanoPhoria receives €3.5m seed grant from the Sofinnova Telethon Fund
May 2022
NanoPhoria granted patent licence
NanoPhoria granted an exclusive patent licence for an inorganic nanoparticle drug‑delivery platform via Italy’s CNR/INAIL technology transfer program.
2021
January 2021
Technology first discovered
Date technology first discovered/written about? Perhaps the first grant awarded to founders?